Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05018091 · ClinicalTrials.gov registry record · Phase 4
Dexamethasone in Total Knee Arthroplasty
A Phase 4 study, sponsored by Rush University Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 404
- Enrollment target
NCT05018091 is a Phase 4 study that has completed, run by Rush University Medical Center. The registered enrollment target is 404 participants.
The verdict
NCT05018091, a Phase 4 study, has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 404 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the most efficacious and safest dexamethasone dose given intraoperatively during total knee arthroplasty that reduces postoperative opioid consumption and pain, improves postoperative nausea and vomiting, and minimizes postoperative complications.
Interventions
- DRUG Dexamethasone 4mg
- DRUG Dexamethasone 8 Mg/mL Injectable Suspension
- DRUG Dexamethasone 16mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 404 participants |
| Start Date | 2021-10-28 |
| Est. Completion | 2025-05-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05018091
The ClinicalTrials.gov registry entry for NCT05018091 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 404 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone 4mg is the first listed.
NCT05018091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05018091 about?
NCT05018091 is a clinical study titled "Dexamethasone in Total Knee Arthroplasty". The purpose of this study is to determine the most efficacious and safest dexamethasone dose given intraoperatively during total knee arthroplasty that reduces postoperative opioid consumption and pain, improves postoperative nausea and vomiting, and minimizes postoperative complications.
What is the current status of trial NCT05018091?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 404 participants. The study started on 2021-10-28. Estimated completion is 2025-05-30.
What interventions are being tested in trial NCT05018091?
The interventions under investigation include: Dexamethasone 4mg (DRUG), Dexamethasone 8 Mg/mL Injectable Suspension (DRUG), Dexamethasone 16mg (DRUG).
Who is sponsoring clinical trial NCT05018091?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.